HiLabs is a leading provider of AI-powered solutions to clean dirty data, unlocking its hidden potential for healthcare transformation. HiLabs is committed to transforming the healthcare industry through innovation, collaboration, and a relentless focus on improving patient outcomes.
Region: North America
Quantum Circuits
Quantum Circuits, Inc. (QCI) was founded in 2015 with the goal of developing, manufacturing and selling the first practical and useful quantum computers based on superconducting devices. QCI was founded by pioneers in quantum devices and information processing from the Department of Applied Physics at Yale University. Their group has produced many scientific firsts, including the development of a “quantum bus” for entangling qubits with wires and the first implementation of a quantum algorithms and error-correction with a solid-state device.
Dispatch
Dispatch is a data orchestration platform powering cross-application workflows for financial advisors, enabling them to seamlessly sync client data across the advisor tech stack and to free them from continually building and maintaining integrations.
OnCusp Therapeutics
OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients.
Shinobi Therapeutics
Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system.
ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). ARTBIO’s approach uses the optimal alpha-emitting isotope (Pb212) with tumor-specific targets to create unique radioligand therapeutics. The company’s AlphaDirectTM technology, a first-of-its-kind Pb212 isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs.
Albert Invent
Albert Invent is an end-to-end R&D platform for chemists and materials scientists, combining ELN, LIMS, inventory, and regulatory tools in one system. Powered by its AI engine, Breakthrough™, trained on over 15 million molecular structures, Albert enables predictive formulation, inverse design, and faster innovation cycles for the worlds largest chemical companies.
Cadence Neuroscience
Cadence Neuroscience is a medical device company developing new therapies for the treatment of epilepsy and other neurological disorders. The company’s core technology was developed at Mayo Clinic and is under clinical evaluation. Founded in 2017 and headquartered in Redmond, Washington, Cadence is led by seasoned executives with extensive backgrounds in neural implant product development and clinical studies.
Adcentrx Therapeutics
Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease-fighting power of small molecule payloads, Adcentrx strives to develop next-generation targeted therapies for improving patient treatment options.
Aera Therapeutics
Aera’s mission is to unlock the potential of genetic medicines by tackling the greatest unmet need in the field today – delivery. Aera has two proprietary delivery platforms – lipid nanoparticles (LNPs) and protein nanoparticles (PNPs) – that are being developed to enable next-generation genetic medicines across a range of therapeutic modalities and disease areas. These platforms have the potential to overcome the limitations of today’s delivery technologies and expand the application of genetic medicines.